ADA Scientific Sessions 2026 Abstract

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results

By Weikai C. Fang, Yuna Chae, Dae Young Lee, Hyung Heon Kim

Trial in peopleInterventions

The paper

Weikai C. Fang, Yuna Chae, Dae Young Lee, Hyung Heon Kim

Hopkinton

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, late-breaking 3102-LB

doi.org/10.2337/db26-3102-lb

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity